Bilayer Therapeutics is a development-stage company co-founded in 2020 by a team of world-renowned drug development and delivery experts and gastroenterologists to stimulate the body’s innate mechanisms for regulating constipation and diarrhea. With a naturally occurring bile acid (chenodeoxycholate or CDC) delivered via proprietary bilayer tablet technology, the company is developing innovative treatments for Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation and other conditions of the colon.

CDC activates both established mechanisms of action for treating constipation: fluid flow and motility in the colon. By using CDC, Bilayer Therapeutics aims to offer more effective treatments for chronic constipation that will cause fewer side effects for patients.

No related news